John co-founded Satsuma Pharmaceuticals in 2016 and since then has served as our President, Chief Executive Officer and member of our Board of Directors. John’s biopharmaceutical industry experience spans more than 30 years and includes CEO, board of directors, executive leadership, operations, strategy, business / corporate development, and product development and commercialization roles in discovery-, clinical and commercial-stage public and private companies. John’s experience includes serving as Chief Business Officer and Senior Vice President at Transcept Pharmaceuticals, a publicly-traded, neuroscience-focused, specialty pharmaceuticals company, from early 2012 until its merger in October 2014 with Paratek Pharmaceuticals; serving successively from March 2007 to October 2009 as Chief Business Officer, Chief Operating Officer and Chief Executive Officer and member of the Board of Directors at OXiGENE, Inc., a publicly-traded oncology and ophthalmology company; and serving in business / corporate development and product management roles of increasing responsibility at CovX, Renovis, Elan Pharmaceuticals / Athena Neurosciences and Immunex Corporation. John currently serves on the board of Cyrano Therapeutics, Inc. John has also served as a consultant and advisor to biopharmaceutical companies and a healthcare-focused investment fund, providing strategy consulting, business / corporate development and other services. John received a B.S.E. degree from Duke University and an M.B.A. from the University of Virginia’s Darden School of Business.
« Back